‘Not Aimed at Reducing Cost Base’
Inchausti said the R&D restructuring was not aimed at reducing our cost base. On the contrary, our R&D to sales ratio in 2019 remains stable.
Thomsen told Reuters the company expects to spend more on research and development this year than the DKK 14.014 billion ($2.199 billion) it spent in 2017, which was 4% less than in 2016: Our analysis shows that we have a surplus of manual labor and are lacking competences in the digital sphere, informatics, data science, artificial intelligence, and automations.
The new units are one of several initiatives Novo Nordisk said it will undertake in its R&D restructuring. …
Read the full article at: https://www.genengnews.com/gen-news-highlights/novo-nordisk-eliminating-400-jobs-in-rd-restructuring/81256248